美国 · SEC FORM 4
Ginkgo Bioworks Holdings, Inc.
DNA · NYSE · CIK 0001830214 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
11 同一窗口内观察到的 Form 4 交易行
5 sales · 6 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2024-05-15 · Sankar Shyam.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 7,315,221
- 上期报告
- 7,166,128
- 日均成交量
- 2,735,902
- 回补天数
- 2.7
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2024-05-15 | Sankar Shyam | 买入 (P) | Class A Common Stock | 625,000 | USD 0.82 | USD 512,500 | SEC 申报 ↗ |
| 2024-05-14 | SLOAN HARRY | 买入 (P) | Class A Common Stock | 297,619 | USD 0.91 | USD 270,833 | SEC 申报 ↗ |
| 2023-05-18 | Sankar Shyam | 买入 (P) | Class A Common Stock | 400,000 | USD 1.28 | USD 512,000 | SEC 申报 ↗ |
| 2023-05-18 | SLOAN HARRY | 买入 (P) | Class A Common Stock | 350,000 | USD 1.28 | USD 448,000 | SEC 申报 ↗ |
Form 4 申报证据
43 transaction lines in the latest 365-day window; 927 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Coen Steven P. | 卖出 (S) | Class A Common Stock | 2,403 | USD 15.00 | USD 36,045 | SEC 申报 ↗ |
| 2026-09-15 | HENRY CHRISTIAN O | 卖出 (S) | Class A Common Stock | 5,000 | USD 7.08 | USD 35,400 | SEC 申报 ↗ |
| 2026-08-24 | Coen Steven P. | 卖出 (S) | Class A Common Stock | 330 | USD 6.98 | USD 2,303 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Coen Steven P. | 卖出 (S) | Class A Common Stock | 2,403 | USD 15.00 | USD 36,045 | SEC 申报 ↗ |
| 2026-09-15 | HENRY CHRISTIAN O | 卖出 (S) | Class A Common Stock | 5,000 | USD 7.08 | USD 35,400 | SEC 申报 ↗ |
| 2026-08-24 | Coen Steven P. | 卖出 (S) | Class A Common Stock | 330 | USD 6.98 | USD 2,303 | SEC 申报 ↗ |
| 2026-08-21 | Coen Steven P. | 期权行权/转换 (M) | Class A Common Stock | 743 | USD — | USD — | SEC 申报 ↗ |
| 2026-07-17 | Coen Steven P. | 卖出 (S) | Class A Common Stock | 752 | USD 7.90 | USD 5,941 | SEC 申报 ↗ |
| 2026-07-16 | Coen Steven P. | 期权行权/转换 (M) | Class A Common Stock | 1,486 | USD — | USD — | SEC 申报 ↗ |
| 2026-05-22 | Coen Steven P. | 卖出 (S) | Class A Common Stock | 307 | USD 8.33 | USD 2,557 | SEC 申报 ↗ |
| 2026-05-21 | Coen Steven P. | 期权行权/转换 (M) | Class A Common Stock | 743 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-17 | Coen Steven P. | 卖出 (S) | Class A Common Stock | 324 | USD 7.95 | USD 2,576 | SEC 申报 ↗ |
| 2026-04-16 | Coen Steven P. | 期权行权/转换 (M) | Class A Common Stock | 743 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-13 | Coen Steven P. | 卖出 (S) | Class A Common Stock | 33,171 | USD 6.41 | USD 212,626 | SEC 申报 ↗ |
| 2026-04-10 | Coen Steven P. | 期权行权/转换 (M) | Class A Common Stock | 73,921 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-10 | Shetty Reshma P. | 卖出 (S) | Class A Common Stock | 124,727 | USD 6.43 | USD 801,995 | SEC 申报 ↗ |
| 2026-04-10 | Canton Barry | 卖出 (S) | Class A Common Stock | 124,727 | USD 6.43 | USD 801,995 | SEC 申报 ↗ |
| 2026-04-09 | Shetty Reshma P. | 期权行权/转换 (M) | Class A Common Stock | 251,786 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-09 | Canton Barry | 期权行权/转换 (M) | Class A Common Stock | 251,786 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-09 | Shetty Reshma P. | 卖出 (S) | Class A Common Stock | 13,116 | USD 6.40 | USD 83,942 | SEC 申报 ↗ |
| 2026-04-09 | Kelly Jason R | 卖出 (S) | Class A Common Stock | 109,767 | USD 6.40 | USD 702,509 | SEC 申报 ↗ |
| 2026-04-09 | Canton Barry | 卖出 (S) | Class A Common Stock | 13,116 | USD 6.40 | USD 83,942 | SEC 申报 ↗ |
| 2026-04-08 | Shetty Reshma P. | 卖出 (S) | Class A Common Stock | 13,155 | USD 6.93 | USD 91,164 | SEC 申报 ↗ |
| 2026-04-08 | Shetty Reshma P. | 期权行权/转换 (M) | Class A Common Stock | 27,738 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-08 | Kelly Jason R | 卖出 (S) | Class A Common Stock | 97,015 | USD 6.93 | USD 672,314 | SEC 申报 ↗ |
| 2026-04-08 | Kelly Jason R | 期权行权/转换 (M) | Class A Common Stock | 212,949 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-08 | Canton Barry | 卖出 (S) | Class A Common Stock | 13,155 | USD 6.93 | USD 91,164 | SEC 申报 ↗ |
| 2026-04-08 | Canton Barry | 期权行权/转换 (M) | Class A Common Stock | 27,738 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-07 | Shetty Reshma P. | 期权行权/转换 (M) | Class A Common Stock | 27,738 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-07 | Kelly Jason R | 期权行权/转换 (M) | Class A Common Stock | 212,949 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-07 | Canton Barry | 期权行权/转换 (M) | Class A Common Stock | 27,738 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-16 | Coen Steven P. | 卖出 (S) | Class A Common Stock | 708 | USD 6.74 | USD 4,772 | SEC 申报 ↗ |
| 2026-03-13 | Coen Steven P. | 期权行权/转换 (M) | Class A Common Stock | 1,486 | USD — | USD — | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | DNA |
| CIK | 0001830214 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | NYSE |
数据覆盖
| 本地 Form 4 历史 | 927 transaction lines from 2021-09-16 to 2026-10-05 4 P purchase lines · 686 S sale lines · 237 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.